| Unique ID issued by UMIN | UMIN000026750 |
|---|---|
| Receipt number | R000030710 |
| Scientific Title | Observation of clinical outcome of bronchial asthma with allergic rhinitis caused by house dust mite |
| Date of disclosure of the study information | 2017/03/30 |
| Last modified on | 2020/04/03 10:40:01 |
Observation of clinical outcome of bronchial asthma with allergic rhinitis caused by house dust mite
Treatment for asthma with rhinitis by dust mite
Observation of clinical outcome of bronchial asthma with allergic rhinitis caused by house dust mite
Treatment for asthma with rhinitis by dust mite
| Japan |
Bronchial asthma with allergic rhinitis caused by house dust mite
| Pneumology | Clinical immunology | Oto-rhino-laryngology |
Others
NO
To evaluate the efficacy of treatment for allergic disease in the upper and lower airway from a clinical view and immunological biomarkers
Safety,Efficacy
Confirmatory
Others
Not applicable
Change in symptoms and medication for allergic rhinitis and asthma by treatment with medicine or sublingual immunotherapy for 3 years
1. Change in allergic response in nasal mucosa and skin prick test
2. Change in allergic parameters in peripheral blood
3. Compliance of sublingual immunotherapy
4. Safety (adverse event)
Observational
| Not applicable |
| 65 | years-old | >= |
Male and Female
1. Bronchial asthma with allergic rhinitis with disease duration of more than 1 year
2. Sensitization to HDM (specific IgE by ImmunoCAP is greater than or equal to class 2)
3. Positive nasal challenge test to house dust allergen
4. Bronchial asthma as follows;
a. Mild to moderate severity, not in acute exacerbation
b. FEV1 is greater than or equal to 70% of predicted value
c. Reversible respiratory symptoms
d. Negative specific IgE (class 0 or 1) to dog, cat, Alternaria, and Aspergillus
5. Be willing to receive medication therapy or allergen immunotherapy for bronchial asthma with allergic rhinitis
1. Pregnant or breastfeeding female
2. Patients with sino-nasal disease that might confound accurate determination of the outcomes of the study
3. Patients with severe asthma
4. Smoker or pet keeper
5. Patients with episode of life-threatening treatment-related adverse event
6. Patients with malignant disease or severe systemic disease which affect immune system
7. Patients who cannot receive sublingual immunotherapy by other reasons
60
| 1st name | Sawako |
| Middle name | |
| Last name | Masuda |
National Hospital Organization Mie National Hospital
Department of Otorhinolaryngology
514-0125
357 Osato-Kubota, Tsu, Mie 514-0125, Japan
059-232-2531
masudas@mie-m.hosp.go.jp
| 1st name | Satoko |
| Middle name | |
| Last name | Usui |
National Hospital Organization Mie National Hospital
Department of Otorhinolaryngology
514-0125
357 Osato-Kubota, Tsu, Mie 514-0125, Japan
059-232-2531
usuis@mie-m.hosp.go.jp
National Hospital Organization Mie National Hospital
Torii Pharmaceutical Co., LTD
Profit organization
Ethics Review Committee of National Hospital Organization Mie National Hospital
357 Osato-Kubota, Tsu, Mie 514-0125, Japan
059-232-2531
suga.shigeru.ke@mail.hosp.go.jp
NO
| 2017 | Year | 03 | Month | 30 | Day |
Unpublished
Open public recruiting
| 2016 | Year | 12 | Month | 14 | Day |
| 2016 | Year | 05 | Month | 26 | Day |
| 2016 | Year | 12 | Month | 14 | Day |
| 2023 | Year | 10 | Month | 31 | Day |
Improvement of allergic rhinitis and asthma is expected by treatment with medicine or sublingual immunotherapy. We evaluate the clinical symptoms and biomarkers in the regular medical practice for 3 years.
| 2017 | Year | 03 | Month | 29 | Day |
| 2020 | Year | 04 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030710